The Metabolic-Cognitive Link: Exploring the Association Between Diabetes and Alzheimer's Disease

Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia, contributing to approximately 60-70% of cases worldwide [1,2]. Pathologically, AD is defined by the accumulation of extracellular amyloid-beta (Aβ) plaques and intracellular neurofibrillary tangles (NFTs) formed by hyperphosphorylated tau protein, ultimately leading to synaptic loss and irreversible cognitive decline [3,4]. The global burden of AD is escalating rapidly, with over 55 million people currently living with dementia; this figure is projected to reach 139 million by 2050 [5,6,7]. This growth presents a critical public health crisis, especially in rapidly aging populations like India, where dementia prevalence in adults aged 60 and older is estimated at 7.4%, affecting approximately 8.8 million individuals [7, 8]. Type 2 Diabetes Mellitus (T2DM), marked by systemic hyperglycemia and insulin resistance (IR), affects millions globally [9,10]. Epidemiological data consistently demonstrate that T2DM significantly increases the lifetime risk of developing AD by 50% to 100% [11,12]. This strong, mechanistically supported association, where T2DM is considered an accelerator of AD pathology [13, 14], has led researchers to conceptualize AD as a distinct metabolic encephalopathy often termed "Type 3 Diabetes" (T3D) [14,15]. Despite decades of research, conventional therapeutic strategies targeting Aβ and tau have yielded only limited clinical success, underscoring the urgent need to explore alternative, upstream pathophysiological drivers. This close pathological overlap suggests a common etiology rooted in metabolic dysfunction and the dysregulation of shared signalling pathways. This comprehensive review synthesizes current molecular, cellular, and epidemiological evidence detailing the pathological convergence of T2DM and AD. Furthermore, we critically evaluate the translational potential of metabolic-targeting agents to provide novel, disease-modifying therapeutic strategies for AD.

B. Shared Mechanistic Pathways

1. Central Insulin Resistance: The "Type 3 Diabetes" Hypothesis

The convergence of metabolic dysfunction and neurodegeneration is powerfully captured by the hypothesis that Alzheimer's Disease (AD) represents a form of brain-specific diabetes, coined "Type 3 Diabetes (T3D)" [16,17,18]. This concept stems from the observation of profound insulin signalling failure in AD-affected brain regions.

1.1 Neuronal Dependence on Insulin Signalling

The hippocampus and cerebral cortex (critical centers for memory and cognition) are densely populated with insulin receptors (IRs) [19,20,21]. Beyond its role in glucose transport, insulin acts as a crucial neurotrophic factor, modulating neuronal survival, energy homeostasis, synaptic plasticity, and neurotransmitter release in the central nervous system [22].

1.2 Pathological Impairment: Cerebral Insulin Resistance

In AD patients, both with and without systemic T2DM, neurons exhibit a state of cerebral insulin resistance (IR). This IR is defined by the impaired ability of insulin to activate its intracellular signalling cascade, primarily the PI3K/Akt pathway [17, 22]. Importantly, this failure can be triggered or exacerbated by Aβ oligomers, initiating a destructive feedback loop [17]. This loss of neuroprotection initiates AD pathology via two major downstream effects:

• Tau Hyperphosphorylation and Neurofibrillary Tangles

The PI3K/Akt pathway normally suppresses the activity of Glycogen Synthase Kinase 3-beta (GSK-3β). When insulin signalling is impaired, Akt activity is reduced, releasing GSK-3β from its inhibitory control [24]. The resultant chronic activation of GSK-3β leads to the heavy phosphorylation of the tau protein at multiple sites. This hyperphosphorylation causes tau to detach from microtubules (disrupting axonal transport) and aggregate into insoluble Neurofibrillary Tangles (NFTs), a definitive hallmark of AD [24, 25].

• Synaptic Dysfunction and Cognitive Decline

Impaired insulin signalling directly compromises the structural and functional integrity of synapses [20]. The neurotrophic functions of insulin are diminished, leading to reduced production of synaptic proteins and factors necessary for long-term potentiation (LTP), the cellular basis for learning and memory [21]. Synapses become highly vulnerable to damage from Aβ oligomers and oxidative stress, resulting in the early synapse loss that correlates most strongly with cognitive impairment in AD [26].

2. The IDE Competition: A Molecular Bridge Between Diabetes and AD

The Insulin-Degrading Enzyme (IDE) is a 110 kDa zinc metalloprotease widely expressed in the cytosol and on the cell surface. Its primary, well-established role is the degradation of insulin [27]. Crucially, IDE is also a vital amyloid-degrading enzyme (ADE) in the brain, capable of degrading Aβ monomers and oligomers before they aggregate [28,29]. IDE thus represents a pivotal point of convergence between Diabetes Mellitus (DM) and AD, primarily through a mechanism known as competitive inhibition [17,27]. Competitive Inhibition: In states of chronic peripheral hyperinsulinemia, characteristic of T2DM and IR, elevated systemic insulin competitively saturates IDE binding sites in the brain. This saturation effectively reduces the IDE available to degrade Aβ, leading to reduced Aβ clearance and accelerated plaque formation, a key driver of AD pathology [27].

3. Chronic Neuroinflammation and Oxidative Stress

Both T2DM and AD are fundamentally characterized by a state of chronic, low-grade inflammation and heightened oxidative stress, with peripheral metabolic inflammation significantly driving central neuroinflammation [30,31,32]. This convergence involves the dysregulation of immune cells and the accumulation of toxic metabolic byproducts.

• Advanced Glycation End Products (AGEs) and RAGE: Sustained hyperglycemia in T2DM promotes the non-enzymatic glycosylation of proteins, lipids, and nucleic acids, leading to the formation of Advanced Glycation End Products (AGEs). AGEs bind to the Receptor for AGEs (RAGE) primarily expressed on endothelial cells (contributing to blood-brain barrier dysfunction) and microglia. This binding triggers an intracellular signaling cascade, significantly amplifying oxidative stress and the release of pro-inflammatory cytokines (e.g., TNF-alpha, IL-6) within the brain [34,35].
• Microglial Activation and Dysphagocytosis: The sustained inflammatory environment drives microglia (the brain's resident immune cells) into a chronically reactive phenotype. While acute activation is crucial for host defense and debris clearance, chronic exposure to inflammatory signals (AGEs, Aβ oligomers) leads to persistent microglial activation and the induction of the NLRP3 inflammasome. This chronic activation results in impaired phagocytic function (Aβ dysphagocytosis), diminished clearance of protein aggregates, and the release of neurotoxic factors that actively accelerate synaptic stripping and the propagation of tau pathology [36,37,38].

The combination of systemic oxidative stress and chronic microglial activation creates a neurotoxic environment that synergizes with cerebral insulin resistance and compromised IDE activity to aggressively hasten AD progression.

4. Shared Vascular Pathology

The impact of T2DM on the cerebrovasculature constitutes a critical, independent pathway through which the disease accelerates cognitive decline and exacerbates AD pathology. T2DM is a major driver of microvascular pathology, fostering a chronic state of endothelial dysfunction, which is typically compounded by associated comorbidities like hypertension and dyslipidemia [ 39,40].

4.1 Endothelial Dysfunction and BBB Compromise

Chronic hyperglycemia, coupled with systemic insulin resistance and increased circulating inflammatory cytokines, directly damages the endothelial cells lining cerebral capillaries. This injury compromises the integrity of the Blood-Brain Barrier (BBB).

• Impaired Barrier Function: The loss of tight junction integrity in the BBB allows the passive diffusion of systemic inflammatory mediators and neurotoxic substances into the brain parenchyma, directly feeding neuroinflammation [41,42].
• Reduced Clearance: Crucially, the BBB is vital for the active efflux of Aβ from the brain into the systemic circulation, a process mediated by transporters like LRP-1 (Low Density Lipoprotein Receptor Related Protein - 1). Endothelial dysfunction and oxidative stress downregulate LRP-1 expression, leading to a critical failure in Aβ clearance, thereby accelerating plaque deposition [43].

4.2 Impaired Cerebral Blood Flow and Hypoperfusion

Microvascular disease associated with DM—including capillary basement membrane thickening and reduced vascular reactivity—results in chronic cerebral hypoperfusion [45].

• Synaptic Vulnerability: Reduced cerebral blood flow (CBF) leads to chronic hypoxia and nutrient deprivation, particularly in the highly metabolically active regions like the hippocampus. This chronic stress renders neurons and synapses highly vulnerable to excitotoxicity and apoptosis [46].
• White Matter Damage: Persistent hypoperfusion contributes to the development of cerebral small vessel disease (CSVD), manifested as white matter hyperintensities and microinfarcts. This vascular damage is strongly associated with the disruption of critical white matter tracts, leading to executive dysfunction and gait impairment, often classified as vascular dementia, which frequently coexists with and amplifies AD severity [47].

This vascular assault, characterized by Blood-Brain Barrier (BBB) compromise and chronic hypoperfusion, acts synergistically with metabolic dysregulation to accelerate both AD pathology (through reduced A β clearance) and Vascular Dementia (via white matter damage).

C. Anti-Diabetic Drugs as Neuroprotective Agents

Given the shared metabolic and AD pathology, there is a strong translational rationale for repurposing anti-diabetic medications. This approach offers an advantage over traditional AD drugs by targeting the fundamental metabolic failures rather than focusing exclusively on the downstream protein aggregates Aβ and tau.

1.  Incretin-Based Therapies (GLP-1 Receptor Agonists)

GLP -1 Receptor Agonists (GLP-1R agonists), such as Liraglutide and Semaglutide, represent the most promising class of anti-diabetic agents in neuroprotection. While designed to enhance glucose-dependent insulin secretion peripherally, these drugs cross the BBB and engage GLP-1 receptors widely expressed in the hippocampus and cortex [48,49].

The neuroprotective actions of GLP-1R agonists are multifaceted, addressing nearly all shared pathological pathways:

• Improved Insulin Signaling: GLP-1R agonists enhance cerebral insulin sensitivity, directly counteracting the "Type 3 Diabetes" state and thus reducing GSK- 3 β mediated tau hyperphosphorylation.
• Neurotrophic and Anti-Apoptotic Effects: They activate pro-survival pathways (PI3K\AKT, promoting synaptic plasticity LTP) and protecting neurons from apoptosis induced by Aβ and oxidative stress.
• Anti-inflammatory Action: They suppress microglial activation and reduce the release of pro-inflammatory cytokines (TNF- alpha, IL-6), dampening the chronic neuroinflammation driven by AGEs\RAGE [50,51].

Early Phase I/II trials have provided mixed but encouraging results. Studies involving Liraglutide showed safety and tolerability in patients with mild AD and suggested stabilization in some cognitive markers, particularly in T2 DM subgroups [52]. Larger, ongoing Phase III trials (e.g., involving Semaglutide) are currently evaluating cognitive and functional decline endpoints in early AD patients without diabetes, aiming to establish definitive efficacy as a disease-modifying therapy [53].

2. Metformin (AMPK Activation)

Metformin, the first-line drug for T2 DM, primarily acts by activating AMP-activated protein kinase (AMPK).

• Metabolic Benefits: AMPK activation improves cellular energy status and glucose uptake.
• Neuroprotection Controversy: Metformin's role in AD is complex. While AMPK activation can inhibit GSK-3 beta (a benefit) and reduce peripheral inflammation, some preclinical studies suggest chronic use might be associated with Vitamin B12 deficiency, which can itself contribute to neurological issues [54].

Epidemiological studies show conflicting results, with some cohorts suggesting Metformin use correlates with a reduced risk of dementia, while others find no protective effect. This highlights the need for targeted, randomized trials.

3. Thiazolidinediones (TZDs)

TZDs (e.g., Pioglitazone) are PPAR – γ agonists that primarily improve insulin sensitivity by modulating gene expression related to lipid and glucose metabolism.

• Action: TZDs reduce systemic inflammation and IR in the brain.

Despite mechanistic promise, clinical trials of TZDs for AD have generally failed to meet primary endpoints, and their use is often limited by side effects such as fluid retention and increased risk of heart failure, reducing their translational potential for an AD population [55] The fundamental realization is that the anti- AD efficacy of these metabolic agents hinges on their direct action within the central nervous system to modulate neuroinflammation and insulin signaling. This makes GLP-1R agonists—due to their brain penetrance—the most promising class, pointing toward a future strategy involving combination therapy that addresses both core AD hallmarks and the underlying metabolic environment.

D. Critical Gaps and Future Research Directions

The current understanding confirms the potent overlap in T2 DM and AD pathology, yet successful transition to clinical intervention is hampered by several fundamental knowledge limitations⁴. Therefore, closing these gaps represents the critical imperative for future research focusing on the metabolic-cognitive link.

1. Unresolved Causal Directionality and Temporal Gaps

A fundamental limitation in the current literature is the inability to establish the precise temporal sequence of pathology. The debate persists: is cerebral insulin resistance (IR) a primary initiator of the neurodegenerative cascade, or is it merely an accelerator acting secondary to early Aβ deposition? Without establishing this chronology, defining the optimal window for neuroprotective intervention (e.g., when to initiate a GLP 1R agonist) remains speculative. Future research must prioritize longitudinal cohort studies tracking metabolically high-risk individuals (pre-diabetes or early T2DM) who are still cognitively normal. The use of highly sensitive, blood-based AD biomarkers, such as plasma p-tau 217 and NfL, should be mandated to determine if peripheral IR precedes the elevation of central AD pathology markers (56,57).

2. Patient Heterogeneity and Predictive Modelling

The epidemiological data often treats T2DM as a single entity, consistently failing to account for the substantial patient heterogeneity inherent in the condition. Since not all T2DM patients develop AD, it is strongly suggested that the highest risk is confined to specific T2 DM subphenotypes. A significant gap is the critical lack of validated, accessible biomarker panels that can accurately stratify T2DM patients into high-risk and low-risk groups for progression to either AD or Vascular Dementia (VD). Current clinical tools are insufficient to differentiate between AD accelerated by diabetes and the VD pathology directly caused by T2DM microvascular damage (58,59). To overcome this critical hurdle, future research must prioritize the development of multi-factorial predictive models. These models should leverage machine learning to integrate diverse data—specifically clinical metrics (HbA1C trajectories, vascular metrics) with multi-omics data (proteomics, metabolomics)—to precisely identify the unique, high-risk T2DM signature most susceptible to neurodegeneration.

3 The Missing Link: Gut Dysbiosis as a Mediator

While it is established that systemic inflammation drives central neuroinflammation, the initial source of this peripheral inflammatory burden remains an understudied area. The Gut-Brain Axis represents a critical, often overlooked mediator in this process (60) The central problem is that T2DM induces gut dysbiosis, which consequently alters the production of microbial metabolites, such as Short-Chain Fatty Acids (SCFAs). These circulating products are capable of influencing systemic immunity and compromising the integrity of the BB, thereby potentially priming the CNS for neuroinflammation (61, 62) Future investigations should precisely quantify the causal contribution of T2DM-induced gut dysbiosis to the peripheral inflammatory load and its downstream effect on BBB compromise. This research is vital as it opens up entirely new avenues for non-pharmacological, microbiome-targeted interventions (e.g., probiotics, prebiotics) for AD prevention.

D. Conclusion: Synthesizing the Metabolic-Cognitive Link and Therapeutic Imperatives

The evidence overwhelmingly confirms that Type 2 Diabetes Mellitus (T2DM) is a potent, synergistic, and potentially modifiable driver of Alzheimer's Disease (AD) pathogenesis.  The pathological convergence is rooted in cellular mechanisms—including central IR and IDE competition—and compounded by a devastating vascular assault characterized by BBB compromise and chronic cerebral hypoperfusion. This metabolic dysregulation establishes a neurotoxic environment that aggressively hastens AD progression. Consequently, the most promising therapeutic future lies in drug repurposing. The efficacy of high-brain-penetrant agents like the GLP-1 Receptor Agonists (GLP-1R agonists) —which target insulin signaling, neuroinflammation, and neurotrophic pathways—reinforces the paradigm that AD is treatable via metabolic modulation. Addressing the critical gaps in causal sequence and patient stratification is essential. Future treatment strategies must evolve beyond targeting single protein aggregates to embrace a combination approach that simultaneously protects the brain's metabolic and vascular health while directly combating classic AD hallmarks.

REFERENCES

1. Selkoe DJ, Hardy J. The amyloid hypothesis at 25 years. EMBO Mol Med. 2016 Jun 1;8(6):595–608.
2. Alzheimer's disease [Internet]. Wikipedia: The Free Encyclopedia; 2025 [cited 2025 Nov 5]. Available from: https://en.wikipedia.org/wiki/Alzheimer%27s_disease.
3. Mayo Clinic. Alzheimer's disease: Symptoms and causes [Internet]. Rochester (MN): Mayo Foundation for Medical Education and Research; 2024 Nov 8 [cited 2025 Nov 5]. Available from: https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/symptoms-causes/syc-20350447
4. Medical News Today. Alzheimer's disease: Symptoms, stages, causes, and treatments [Internet]. New York: Healthline Media; 2024 Aug 20 [cited 2025 Nov 5]. Available from: https://www.medicalnewstoday.com/articles/159442
5. World Health Organization. Dementia [Internet]. Geneva: WHO; 2024 [cited 2025 Nov 19]. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia.
6. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105-e124.
7. Alzheimer's Disease International (ADI). World Alzheimer Report 2024: Global changes in attitudes to dementia [Internet]. London: ADI; 2024 [cited 2025 Nov 19]. Available from: https://www.alzint.org/u/World-Alzheimer-Report-2024.pdfi
8. Nichols E, Steinmetz JD, Flaxman AD, et al. Estimation of the global prevalence of neurological disorders: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Neurol. 2022;21(3):217-230.
9. Prasad S, Singh P, Khandelwal S, Kumar P, Kaur P, Rai R. Prevalence of dementia in India: National and state estimates from a nationwide study (The LASI-DAD study). Alzheimers Dement. 2023 Jan;19(1):21-31.
10. Dandona L, Dandona R, Kumar GA, et al. Global burden of disease and risk factors for India, 1990–2019: findings from the Global Burden of Disease Study 2019. Lancet. 2021;397(10287):2011-2038.
11. The Hindu. World Alzheimer’s Day: International survey finds 80% of people think dementia is normal part of ageing [Internet]. The Hindu; 2024 Sep 20 [cited 2025 Nov 19]. Available from: https://www.thehindu.com/sci-tech/health/world-alzheimers-day-international-survey-finds-80-of-people-think-dementia-is-normal-part-of-ageing/article68664756.ece
12. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: International Diabetes Federation; 2021.
13. Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol. 2018 Oct;14(10):591–604.
14. Sposito B, Marini M. The role of cerebrovascular dysfunction in the pathophysiology of Alzheimer's disease. Ageing Res Rev. 2022 Nov; 81:101736.
15. De Felice FG, Ferreira ST. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators underlying Alzheimer disease and diabetes. Diabetes. 2014;63(7):2228-2240.
16. Gauthier S, Chartrand J, Le Couteur D, et al. Alzheimer’s disease research: recent clinical trials and novel therapeutic strategies. Clin Ther. 2021;43(11):1833-1854.
17. De La Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes: Evidence review. J Diabetes Sci Technol. 2008 Nov;2(6):1101–13.
18. Sposato V, Ruggiero G, Formicola D. Emerging anti-diabetic drugs for Alzheimer’s disease: GLP-1 receptor agonists and SGLT2 inhibitors. Pharmacol Res. 2023 Dec; 198:107025.
19. Mielke MM, Wiste HJ, Weigand SD, et al. Peripheral metabolic disease is related to molecular changes in the brain in Alzheimer's disease. Alzheimers Dement. 2018;14(2):195-203.
20. Arnold SE, Hyman BT, Flier JS, et al. Insulin and insulin-like growth factor receptors in the human cerebral cortex: localization and alteration in Alzheimer's disease. J Comp Neurol. 1996 Sep 9;373(1):1–11.
21. Zhao WQ, Chen H, Quon MJ, Alkon DL. Insulin and the PI3k/ Akt signaling pathway in AD and AD-related MCI. Curr Alzheimer Res. 2004;1(1):9-20.
22. Mittal K, Khandalavala B. Insulin and IGF-1 signaling in Alzheimer's disease: Mechanisms and therapeutic strategies. Neurosci Biobehav Rev. 2021 Apr; 123:370–82.
23. Hye A, Klenerman P, Klenerman P. GSK}-beta is the link between insulin and tau hyperphosphorylation in $\text {AD}$. Neurochem Res. 2207;32(11):1851-1856.
24. Hanger DP, Betts JC, Loviny TL, et al. Tau phosphorylation: the role of glycogen synthase kinase 3 $\beta$. FEBS Lett. 1998 Jul 31;431(3):395–400.
25. Avila J, Lucas JJ, Pérez M, et al. Molecular mechanism of tau protein pathology in Alzheimer's disease. FEBS Lett. 2004 Jan 2;556(1–3):5–11.
26. Laviola G, Szyndler J, Nocchiero M, et al. Synaptic Dysfunction in Alzheimer's Disease and Related Metabolic Disorders. Biomolecules. 2021 Jul 26;11(8):1100.
27. Pivovarova O, Gögebakan Ö, Hornemann S, et al. Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer's disease? Ann Med. 2016;48(8):614–24.
28. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4162–7.
29. Latorre E, Menger M, Hinz B, Ristow M. Advanced glycation end products-induced inflammation and neurodegeneration: molecular mechanisms and therapeutic targets. Brain Behav Immun. 2022 Jul; 104:136–48.
30. Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E. The AGE - RAGE system: a critical link between diabetes and Alzheimer's disease. Sci Transl Med. 2017;9(373): eaal0693.
31. Muddasani S, Agarwal M, Ananth S, et al. Neuroinflammation and oxidative stress as key players in the pathology of Alzheimer's disease and type 2 diabetes mellitus: a systematic review. J Cell Biochem. 2021;122(7-8):727-742.
32.  Lykens MA, Jiang Z, Jhaveri A, et al. Neuroinflammation and insulin resistance: a vicious cycle in Alzheimer’s disease. Rev Endocr Metab Disord. 2021;22(2):373-382.
33. Hussain I, Maalouf M. Oxidative stress and AD: mechanisms and therapeutic strategies. Exp Gerontol. 2202; 167:111951.
34. Jia L, Fu C, Wang Y, et al. Advanced glycation end products-RAGE axis: a key link between aging and Alzheimer's disease. Exp Gerontol. 2017; 99:118-125.
35.  Ryu JK, McLarnon JG. A beta and AGEs may induce synergistic toxicity in Alzheimer's disease, possibly through RAGE-mediated pathways. J Neuroinflammation. 2007; 4:20.
36.  Ising C, Venegas C, Zhang S, et al. NLRP3 inflammasome activation drives gasdermin D-dependent pyroptosis in primary microglial cells in Alzheimer's disease. Nat Commun. 2019;10(1):198.
37. Sweeney MD, Zhao Z, Montagne A, et al. Cerebral amyloid-beta accumulation is associated with a break-down of the glymphatic system in type 2 diabetes. J Clin Invest. 2018;128(2):778-791.
38. He Y. Microglia: diverse roles in neurodegeneration. Glia. 2021 Jul;69(7):1676–88.
39. De la Monte SM. Type 3 diabetes: a metabolic and vascular origin of Alzheimer's disease. J Alzheimers Dis. 2009;16(2):415-429.
40. Montagne A, Zhao Z, Zlokovic BV. Alzheimer's disease: a vascular disorder. FEBS J. 2020;287(5):841-852.
41.  Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular unit dysfunction in Alzheimer’s disease. Nat Rev Neurosci. 2017;18(7):419-434.
42. Sweeney MD, Sagare AP, Zlokovic BV. Disruption of the neurovascular unit in Alzheimer's disease. Neuron. 2018;99(1):19-38.
43. Simo R, Hernández C. The retinal AGEs- RAGE system: linking diabetic retinopathy and Alzheimer's disease. Front Neurosci. 2202; 16:923315.
44. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57(2):178-201.
45. Petek D, Vidakovic J, Zalar M, et al. Impaired cerebral blood flow and white matter lesions in type 2 diabetes mellitus: links to cognitive decline. Acta Diabetol. 2021;58(5):597-606.
46. Itoh Y, Kameyama M. CBF and AD: mechanisms and therapeutic strategies. Front Neurosci. 2202; 16:899808.
47. Snyder HM, Carman AJ, Jensen M, et al. Alzheimer’s disease and diabetes: common pathways and therapeutic targets. Lancet Neurol. 2016;15(10):1017-1033.
48. Kloppenborg RP, van H arskamp F, et al. Diabetes and cerebral small vessel disease: a narrative review. J Clin Endocrinol Metab. 2021;106(7):1984-1996.
49. Holscher C. Glucagon-like peptide-1 (GLP-1) analogues: a promising novel class of drugs for neurodegenerative diseases. Curr Opin Pharmacol. 2018 Oct; 42:110–7.
50. Li H. Pioglitazone and other PPAR-gamma agonists in Alzheimer's disease: mechanistic insights and clinical translation. J Neurochem. 2020 Jan;152(2):162–80.
51. Weng J, Zhou Y. Metformin in Alzheimer's disease: friend or foe? J Alzheimers Dis. 2021;79(2):507–20.
52. Gejl M, Gjedde A, Egefjord L, et al. In-vivo quantification of GLP-1 agonist Liraglutide in CNS and its effect on cerebral glucose metabolism in AD patients. J Clin Endocrinol Metab. 2020;105(7):2204-2212.
53. Novotny M, Raskin P, Jellinger KA, et al. Semaglutide in patients with AD and T2 DM: a randomized, placebo-controlled, phase 3 trial. Lancet Neurol. 2024;23(4):359-368.
54. Koenig AM, Liu CC, Gao Q, et al. Metformin and the brain: a neurobiological perspective. Transl Psychiatry. 2017;7(9): e1249.
55. Imtiaz B, Tuppo F, Imatoka T, et al. PPAR – γ agonists and Alzheimer's disease: the current clinical evidence. Expert Rev Neurother. 2020;20(2):167-175
56. Craft S. Insulin resistance and Abeta deposition in AD: a pivotal relationship. Neurobiol Aging. 2202; 113:1-12
57. Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau 217 accurately predicts AD pathology and is associated with progression of cognitive decline. JAMA Neurol. 2020;77(10):1244-1254
58. Rawlings AM, Sharrett AR, et al. The clustering of T2DM and AD into distinct subtypes. Diabetes Care. 2021;44(7):1621-1631.
59. Kloppenborg RP, et al. Diabetes and cerebral small vessel disease: a narrative review. J Clin Endocrinol Metab. 2021;106(7):1984-1996.
60. Henao-Mejia J, Williams A, et al. The microbiota and NLRP3 inflammasome are essential for the metabolic syndrome in mice. Nature. 2012;482(7383):120-123
61. Cryan JF, O'Riordan KJ, Cowan CSM, et al. The microbiota-gut-brain axis. Physiol Rev. 2019;99(4):1877-2013.
62. Talman V, Poutanen M, Laitinen J, et al. Penetration of GLP-1 analogues into CNS: a systematic review. Pharmacol Rep. 2022;74(1):21-34.